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Bcl-3 Acts as an Innate Immune Modulator by
Controlling Antimicrobial Responses in Keratinocytes
Amanda S. Bu¨chau1,2, Daniel T. MacLeod1, Shin Morizane1, Paul F. Kotol1, Tissa Hata1 and Richard L. Gallo1
Innate immune responses involve the production of antimicrobial peptides (AMPs), chemokines, and cytokines.
We report here the identification of B-cell leukemia (Bcl)-3 as a modulator of innate immune signaling in
keratinocytes. In this study, it is shown that Bcl-3 is inducible by the Th2 cytokines IL-4 and IL-13 and is
overexpressed in lesional skin of atopic dermatitis (AD) patients. Bcl-3 was shown to be important to cutaneous
innate immune responses as silencing of Bcl-3 by small-interfering RNA (siRNA) reversed the downregulatory
effect of IL-4 on the HBD3 expression. Bcl-3 silencing enhanced vitamin D3 (1,25D3)-induced gene expression of
cathelicidin AMP in keratinocytes, suggesting a negative regulatory function on cathelicidin transcription.
Furthermore, 1,25D3 suppressed Bcl-3 expression in vitro and in vivo. This study identified Bcl-3 as an important
modulator of cutaneous innate immune responses and its possible therapeutic role in AD.
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INTRODUCTION
The innate immune system encompasses all mechanisms that
enable defense against microbial threats without prior
exposure to the pathogen. As key components of the innate
immune response, epithelial and non-epithelial cells express
several antimicrobial peptides (AMPs) and proteins, including
cathelicidins, b-defensins, and several S100 proteins (re-
viewed in Kolls et al., 2008). These AMPs and antimicrobial
proteins share a broad-spectrum antimicrobial activity, but
are differently regulated in epidermal keratinocytes. Recent
studies have shown that the Th2 type cytokines, IL-4, IL-10,
and IL-13, can downregulate AMP expression in atopic
dermatitis (AD), and that this phenomena may account for the
observed propensity toward skin infections in these patients
(Howell et al., 2005, 2006a). Conversely, Th1 type cytokines,
including tumor necrosis factor-a (TNF-a), IL-1b and Toll-like
receptor (TLR) ligands, predominantly enhance innate im-
mune responses.
Bcl-3 was originally identified as a proto-oncogene in a
subgroup of B-cell leukemia (McKeithan et al., 1990), but
was later found to be expressed in various cell types,
including B and T lymphocytes, erythroblasts, hepatocytes,
and keratinocytes (Bours et al., 1993; Zhang et al., 1994,
1998; Brasier et al., 2001; Nishikori et al., 2003; Massoumi
et al., 2006). Subsequently, it was shown that Bcl-3 associates
with NF-kB p50 or p52 homodimers and is involved in cell
proliferation, oncogenesis, and TLR signaling (Westerheide
et al., 2001; Rocha et al., 2003; Carmody et al., 2007).
Therefore, we hypothesized that Bcl-3 may play a critical role
in controlling cutaneous inflammation and host defense
responses.
In this study, we show that Bcl-3 acts as a transcriptional
modulator of innate immune function of keratinocytes by
modulating expression of the AMPs HBD3 and cathelicidin,
as well of as the cytokines IL-8 and IL-6. We show that Bcl-3
is inducible by the Th2 type cytokines, IL-4 and IL-13, and is
overexpressed in lesional skin from AD patients. Silencing
Bcl-3 by siRNA in keratinocytes reversed the downregulatory
effect of IL-4 on HBD3 expression. Furthermore, Bcl-3
silencing enhanced 1,25D3-induced cathelicidin AMP expres-
sion in keratinocytes, suggesting a negative regulatory
function on cathelicidin transcription. 1,25D3 suppressed
Bcl-3 expression in vitro and in vivo, suggesting an
autoregulatory role of 1,25D3 on Bcl-3 function. Taken
together, these observations suggest a regulatory role for Bcl-
3 in cutaneous innate host defense function and reveal a
possible explanation for altered innate immune responses in
AD and other inflammatory skin diseases.
RESULTS
Bcl-3 is induced by IL-4 and IL-13 and is overexpressed in
lesional AD skin
Bcl-3 was recently identified as an important factor of innate
immune responses in macrophages (Carmody et al., 2007).
Furthermore, Th2 type cytokines have been shown to induce
Bcl-3 expression in mast cells, macrophages, and B and T
lymphocytes (Richard et al., 1999; Kuwata et al., 2003). On
the basis of these findings, we investigated Bcl-3 expression,
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regulation, and function in human epidermal keratinocytes.
In initial studies, the expression of Bcl-3 in cultured primary
keratinocytes was evaluated using quantitative real-time PCR
and immunofluorescence staining (Figure 1 and data not
shown). To investigate whether Th2 type cytokines influence
Bcl-3 expression also in human keratinocytes and to test
whether this effect is unique to Th2 type cytokines,
keratinocytes were exposed to IL-4, the combination of IL-4
and IL-13, or the Th1 type cytokine TNF-a (Figure 1a). Gene
expression analyses revealed that Bcl-3 was weakly induced
by IL-4, but expression was further enhanced by the
combination of the Th2 type cytokines, IL-4 and IL-13,
whereas TNF-a had no effect. Immunohistochemistry of
cultured keratinocytes revealed that Bcl-3 was abundantly
expressed and localized mainly in the cytoplasm of
keratinocytes and expression was weakly enhanced upon
IL-4 and IL-4/IL-13 treatment. Cytoplasmic localization of
Bcl-3 did not significantly change upon IL-4 or TNF-a
treatment (data not shown).
On the basis of the finding that Bcl-3 is inducible by IL-4/
IL-13, cytokines that are both elevated in AD, we next sought
to investigate whether Bcl-3 levels were changed in AD
versus healthy skin. Skin explants were collected from
lesional and non-lesional skin from AD patients and the
normal skin of healthy subjects and were evaluated for the
expression of Bcl-3. As shown in Figure 1b, Bcl-3 mRNA
expression was significantly elevated in lesional skin from AD
patients compared with the skin from healthy subjects. There
was no difference between levels of Bcl-3 in non-lesional AD
skin compared with the skin of healthy controls.
To evaluate the protein expression of Bcl-3 in healthy and
diseased skin, skin biopsy samples from lesional areas of AD
patients and those from healthy subjects were compared by
immunohistochemistry (Figure 1c). Data obtained here
showed that the protein expression of Bcl-3 was more
pronounced in the skin from lesional AD compared with
healthy skin. In healthy skin, staining was only observed in
the uppermost layers of the epidermis, whereas in AD skin
strong fluorescent intensity was found throughout the whole
epidermis.
Bcl-3 modifies keratinocyte innate immune responses
Integrating the findings that AD skin is relatively deficient in
AMP expression (Ong et al., 2002), together with our finding
that Bcl-3 is overexpressed in AD skin, we next hypothesized
that Bcl-3 may directly affect the expression of AMPs and
proteins and tested this hypothesis by silencing Bcl-3 by
siRNA. Effectiveness of Bcl-3 knockdown was determined by
quantitative Real-Time RT-polymerase chain reaction (qPCR)
and confirmed at the protein level by western blot analysis
and was consistently 50–65% (Figure 2a and data not shown).
We first analyzed HBD3, because this AMP is known to be
effectively downregulated by Th2 cytokines and has been
shown to be upregulated by proinflammatory stimuli, such as
TNF-a (Howell et al., 2006b). Suppressing Bcl-3 by siRNA
did not significantly affect the basal expression of AMPs
(Figure 2b and data not shown). To test whether the
suppression of HBD3 gene transcription requires Bcl-3,
keratinocytes silenced for Bcl-3 were stimulated with IL-4
or TNF-a, and transcript abundance of HBD3 was evaluated
by qPCR (Figure 2b). The HBD3 expression was suppressed in
keratinocytes treated with IL-4 in the presence of control
siRNA, but this effect was abrogated when Bcl-3 was partially
silenced by siRNA, thus indicating that Bcl-3 is required for
IL-4-mediated suppression of HBD3 (Figure 2b, upper graph).
To test whether the effect of Bcl-3 on HBD3 expression is
unique or may be dependent on the cytokine milieu, we also
tested whether Bcl-3 was required for TNF-a-induced HBD3
expression. Silencing Bcl-3 resulted in a moderate down-
regulation of TNF-a-induced HBD3 expression (Figure 2b,
lower graph), thus showing that the effect of Bcl-3 on HBD3
expression is dependent on external stimuli.
Next, we investigated whether cathelicidin AMP expres-
sion is regulated by Bcl-3. Cathelicidin is expressed at low
levels in healthy skin but is highly upregulated in states of
injury, inflammation, or infection. Similar to HBD3, cathe-
licidin expression is lower in skin from AD patients compared
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Figure 1. Bcl-3 is induced by IL-4 and IL-13 and is expressed in the lesional
skin of atopic dermatitis. (a) Cells were stimulated for 18 hours with IL-4
(50 ngml1) and IL-4 (50 ngml1) in combination with IL-13 (50 ngml1) or
TNF-a (20 ngml1), and Bcl-3 mRNA abundance was determined by
quantitative RT-PCR. (b) Skin biopsy samples from lesional and non-lesional
atopic dermatitis (AD) were collected and analyzed for expression levels of
Bcl-3 by qPCR. Values of Bcl-3 were normalized to the housekeeping gene
GAPDH and data plotted are presented as relative Bcl-3 expression compared
with normal skin. (c) Skin biopsy samples from lesional AD and healthy
donors were collected and analyzed by immunofluorescence staining. Bcl-3
expression was visualized by an FITC-labelled antibody. AD, atopic
dermatitis; les., lesional; non-les., non-lesional. *Po0.05, **Po0.01;
***Po0.001, NS, not significant; unpaired Student’s t-test. Bar¼ 50mm.
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with that from psoriatic patients. Recently, 1,25D3 has been
identified as a potent inducer of cathelicidin in human
keratinocytes, whereas stimulation with proinflammatory
cytokines alone, such as TNF-a or interferons, is not capable
of upregulating cathelicidin transcription in keratinocytes.
On account of these findings, the role of vitamin D as an
important target for therapy for cutaneous diseases has been
revisited (Hata and Gallo, 2008).
We sought to investigate whether IL-4/IL-13 pretreatment
of keratinocytes, leading to an increase in Bcl-3, would
subsequently alter the capacity of 1,25D3 to induce
cathelicidin (Figure 3a). Keratinocytes were pretreated with
IL-4/IL-13 for 24 hours before exposure to 1,25D3. Keratino-
cytes that were pretreated with IL-4/IL-13 showed impaired
upregulation of cathelicidin gene expression by 1,25D3
compared with vehicle-pretreated keratinocytes (Figure 3a,
left graph). Conversely, pretreatment of keratinocytes with
TNF-a did not reduce 1,25D3-induced cathelicidin expres-
sion but rather enhanced its expression (Figure 3a, right
graph). To define the role of Bcl-3 signaling in cathelicidin
regulation, keratinocytes were silenced for Bcl-3 by siRNA
and were stimulated with 1,25D3. Silencing Bcl-3 did not
alter basal cathelicidin expression (Figure 3b). As shown
earlier, 1,25D3 strongly induced cathelicidin gene transcrip-
tion and this induction was enhanced by Bcl-3 silencing,
suggesting that Bcl-3 acts as a negative regulator of 1,25D3-
mediated cathelicidin expression in human keratinocytes
(Figure 3b, left graph). TNF-a alone did not induce
cathelicidin transcription and this was not altered by
silencing Bcl-3 (Figure 3b, right graph).
p50 decoy enhances 1,25D3-mediated cathelicidin expression
Earlier it has been shown that Bcl-3 interacts with p50
homodimers of the NF-kB pathway. To test whether p50
blocking results in similar effects compared with Bcl-3
silencing, and would thereby mimic the mechanism used
by Bcl-3 to regulate cathelicidin expression, we used p50
decoy and control peptides. Keratinocytes were pretreated for
0.5, 1, or 2 hours with 1 mM of p50 decoy or control peptides
Bcl-3
GAPDH
*
***
siRNA control
siRNA Bcl-3
Vehicle IL-4
Vehicle TNF-α
*** *
HBD3
HBD3
30
20
10
0
R
el
at
ive
 fo
ld
-c
ha
ng
e
2.0
1.5
1.0
0.5
0.0
R
el
at
ive
 fo
ld
-c
ha
ng
e
siR
NA
 Bc
l-3
siR
NA
 co
ntro
l
Figure 2. Bcl-3 is required for the IL-4-mediated downregulation of HBD3.
(a) Efficiency of siRNA silencing was evaluated by western blot analysis of
Bcl-3 expressed by keratinocytes. (b) Stimulation with IL-4 (50 ngml1)
significantly reduced basal human HBD3 expression in keratinocytes.
Silencing of Bcl-3 by siRNA decreased this effect (upper graph). TNF-a-
induced (20 ngml1) HBD3 expression is moderately suppressed by siBcl-3.
*Po0.05, ***Po0.001, unpaired Student’s t-test. Data shown are means
(±SEM) of results from one representative experiment performed in
triplicates.
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Figure 3. Bcl-3 silencing enhances cathelicidin expression induced by
1,25D3. (a) Cultured human keratinocytes were exposed to IL-4 (50 ngml1)
and IL-13 (50 ngml1) for 24 hours before stimulation with 1,25D3 (10 nM).
After 6 hours of 1,25D3 stimulation, cells were harvested and mRNA
expression of cathelicidin was determined by qPCR (left graph). As control,
keratinocytes were also pretreated with TNF-a (20 ngml1) and stimulated
with 1,25D3 (10 nM, right graph). Data shown are means (±SD) of results
from single experiments performed in triplicates and are representative of at
least two independent experiments. (b) Treatment of keratinocytes with siRNA
to Bcl-3, enhances cathelicidin mRNA expression after induction by 1,25D3
(10 nM, left graph), whereas Bcl-3 siRNA has no effect on cathelicidin
expression with or without TNF-a (20 ngml1, right graph). Data shown are
means (±SEM) of results from single experiments performed in triplicates.
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before stimulation with 1,25D3. After 2 hours of pretreatment
with a p50 decoy, 1,25D3-mediated cathelicidin induction
was significantly enhanced (Figure 4). These results show that
blocking of p50 enhances 1,25D3-mediated cathelicidin
induction, thus further implying that Bcl-3 may suppress the
capacity of 1,25D3 to increase AMP expression in keratino-
cytes.
Vitamin D decreases the expression of Bcl-3
It was recently shown that oral vitamin D3 administration
enhances cutaneous cathelicidin expression in lesional skin
of individuals with AD (Hata and Gallo, 2008). Therefore, we
next analyzed whether 1,25D3 in vitro, or oral administration
of vitamin D to patients, could also affect the Bcl-3
expression. Stimulation of keratinocytes with 1,25D3 led to
a moderate but statistically significant decrease of the Bcl-3
expression (Figure 5a). Furthermore, oral administration of
1,25D3 also caused a decrease of Bcl-3 in lesional AD in
most patients tested (Figure 5b).
Bcl-3 expression enhances stimulation of cytokine production
As AD is a complex chronic inflammatory skin disease, it was
also of interest to analyze how Bcl-3 influences the
production of inflammatory cytokines. To test this, the
expressions of CXCL8/IL-8 and IL-6 were measured in
keratinocytes that were stimulated with TNF-a or 1,25D3
and also silenced for Bcl-3. TNF-a-induced IL-8 and IL-6
expressions were significantly downregulated by Bcl-3
silencing, thus showing that this pathway is positively
controlled by Bcl-3 abundance (Figure 6). As expected,
stimulation with 1,25D3 did not alter IL-8 or IL-6 levels, and
this did not change upon treatment with siRNA targeting
Bcl-3.
DISCUSSION
The epidermis is an active immunological barrier providing
powerful protection against the invasion of microbes. AMPs
are an integral part of this innate immune response, and they
are effective in killing bacterial, viral, and other pathogens. In
normal skin, expression of these peptides is relatively low,
but they accumulate during wound healing and infectious or
inflammatory diseases (Ong et al., 2002; Schauber et al.,
2007; Yamasaki et al., 2007). Unfortunately, expression of
the AMPs, cathelicidin and HBD3, is significantly less in
lesional skin from patients with AD compared with other
inflammatory skin disorders such as psoriasis (Ong et al.,
2002). This phenomenon is believed to contribute to the
higher susceptibility to severe skin infections seen in AD
patients, most commonly caused by Staphylococcus aureus
and vaccinia virus, whereas psoriasis patients rarely suffer
from cutaneous superinfections. It is not clear why patients
with AD express lower AMPs than expected, but the Th2 type
cytokines, such as IL-4, IL-10, and IL-13, which are abundant
in AD skin, have been shown to inhibit expression of some
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Figure 4. p50 decoy enhances 1,25D3-mediated cathelicidin expression.
Keratinocytes were treated with p50 decoy (1 mM) or a control peptide (1 mM)
for 0.5, 1, or 2 hours and were then stimulated with 1,25D3 (1 nM) for 4 hours.
Cathelicidin expression was measured by qPCR. ***Po0.001, unpaired
Student’s t-test.
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Figure 5. 1,25D3 suppresses Bcl-3 expression in keratinocytes. (a) Cultured
keratinocytes treated with 1,25D3 (10 nM) for 24 hours show decreased Bcl-3
expression. **Po0.01, NS, not significant, unpaired Student’s
t-test. (b) Atopic dermatitis patients (AD) received orally 1,25D3 as described
in the Materials and Methods section. Bcl-3 transcript expression was
measured in skin biopsy samples taken from lesional skin from AD patients.
Each dot represents one patient. The mean values of untreated AD (n¼7)
were set as 100% and Bcl-3 levels in 1,25D3-treated AD are presented as
percentage (%) of the untreated control. P¼0.077, paired Student’s t-test.
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Figure 6. Bcl-3 regulates the expressions of IL-6 and IL-8. Keratinocytes
transfected with siRNA oligonucleotides for Bcl-3 were stimulated with (a)
TNF-a (20 ngml1) or (b) 1,25D3 (10 nM), and IL-8 and IL-6 expressions was
measured using real-time RT-PCR. Data shown are means (±SEM) of results
from a representative experiment performed in triplicates. ***Po0.001, NS,
not significant, unpaired Student’s t-test. Open bar, siRNA control; solid bar,
Bcl-3 siRNA.
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AMPs (reviewed in Bieber, 2008). Here, we provide further
explanation for the potential decrease in AMP expression in
AD and show that Bcl-3, a recently identified element of the
NF-kB signaling pathway, is increased in lesional skin from
AD patients compared with normal skin and induced by Th-2
cytokines.
The transcriptional regulation of Bcl-3 itself is currently
poorly understood. Studies on the human Bcl-3 promoter are
very limited. However, sequencing of the murine Bcl-3
promoter revealed IL-4 specifically induced AP1 and AP1-
like binding activity and mutation of these binding sites
abolished IL-4-induced Bcl-3 promoter activity, suggesting
that these transcription factors are important in Bcl-3
promoter transactivation (Rebollo et al., 2000). To test
whether the same transcription factors are responsible for
Th2 cytokine-induced Bcl-3 expression in humans, further
studies are needed. Here, we have shown that IL-4 and IL-13
appear to act together to induce Bcl-3. This synergy may arise
from receptor interaction: in non-lymphoid cells, the IL-4
receptor (IL-4R) is composed of the IL-4Ra chain and the
IL-13Ra1 or IL-13Ra2 chains, explaining, at least in part, why
IL-13 shares several biological activities with IL-4 (Vita et al.,
1995). Moreover, it has been shown that IL-13 and IL-4 can
induce IL-13Ra2 (David et al., 2001), suggesting an autocrine
loop for IL-4/IL-13 effects.
In our study, we showed that Bcl-3 acts as a potential
transcriptional modulator of keratinocyte immune responses.
Bcl-3 was required for IL-4-mediated downregulation of
HBD3 expression, and Bcl-3 negatively regulated TNF-a-
induced HBD3, IL-8, and IL-6 expressions. The effects on the
expression of cathelicidin by keratinocytes was more com-
plex, as classical activators of the innate immune response,
such as TNF-a and TLR ligands, are alone ineffective in
stimulating cathelicidin AMP expression in keratinocytes. In
contrast, we and others have recently identified 1,25D3 as a
strong inducer of cathelicidin expression in humans. 1,25D3
induces cathelicidin owing to a vitamin D-responsive
element in the human cathelicidin promoter and through
the modification of keratinocyte TLR2 and CD14 expression
levels (Schauber et al., 2007). Silencing Bcl-3 resulted in the
enhancement of 1,25D3-induced cathelicidin expression,
thus implying a negative regulatory role for Bcl-3 in
cathelicidin expression. 1,25D3 stimulation also led to a
modest decrease of Bcl-3 transcripts in cultured keratino-
cytes, suggesting that an autoregulatory mechanism of Bcl-3
function may be involved. Furthermore, we show here that
TNF-a together with 1,25D3 led to a higher expression of
cathelicidin than 1,25D3 stimulation alone. As silencing of
Bcl-3 and stimulation with TNF-a alone did not induce
cathelicidin transcription, this suggests that activation of the
cathelicidin vitamin D-responsive element by 1,25D3 is
crucial for cathelicidin induction in human keratinocytes.
Mechanisms accounting for the activities of Bcl-3 are just
beginning to be understood. Bcl-3 interacts with p50 NF-kB
homodimers; however, its specific action is still controversial.
It has been reported that Bcl-3 acts as a negative regulator of
TLR signaling in macrophages through p50 ubiquitination
blockade (Carmody et al. 2007), whereas in other studies, it
has been shown that Bcl-3 facilitates NF-kB-mediated
transactivation by removing inhibitory p50 homodimers from
selected kB sites and thereby enhancing NF-kB activity
(Franzoso et al., 1992; Bours et al., 1993; Fujita et al., 1993;
Hayden and Ghosh, 2008). In this study using primary
keratinocytes, effects mediated by Bcl-3 appear to be
dependent on both the target gene tested and stimuli used
to induce antimicrobial and cytokine responses. Furthermore,
using a p50 decoy, effects similar to Bcl-3 silencing were
observed in keratinocytes treated with 1,25D3, indicating
that regulation of cathelicidin expression may involve
blocking p50 subunits. A transcription activation domain
necessary for the positive regulation of gene expression is
present only in p65, c-Rel, and RelB. As they lack
transcription activation domains, p50 and p52 may repress
transcription unless associated with a transcription activation
domain-containing NF-kB family member or other proteins
capable of co-activator recruitment (Chen and Greene,
2004). Constitutive binding of p50 or p52 homodimers to
kB sites on NF-kB-responsive promoters may thus act to
check NF-kB transactivation until displaced by transcription-
ally competent NF-kB dimers. In addition, negative regula-
tory elements within promoter regions, as have been
discovered for human cathelicidin, may impact the tight
regulation of gene transcription (Elloumi and Holland, 2008).
Their study showed that the cathelicidin promoter region
contains a negative regulatory element; however, the exact
element was not identified (Elloumi and Holland, 2008). Our
initial studies investigating the human cathelicidin promoter
region identified various putative NF-kB binding/p50 sites
(data not shown).
Several studies recently uncovered an important role for
1,25D3 in innate host defense: 1,25D3 is a potent inducer of
the cathelicidin AMP expression (Wang et al., 2004). In
response to TLR2/6 or TLR2/1 activation or injury, vitamin D3
metabolism is altered, and subsequently the active form of
1,25D3 is generated to serve as a signaling molecule in
innate immune responses in keratinocytes and monocytes,
respectively (Liu et al., 2007; Schauber et al., 2007). 1,25D3
directly affects NF-kB activity by inhibiting de novo synthesis
of the NF-kB p50 protein and its precursor p105 in human
lymphocytes (Yu et al., 1995) and by downregulating c-Rel
and RelB in dendritic cells (Xing et al., 2002). It is not known
yet whether this action of 1,25D3 is important for cathelicidin
induction, but it is intriguing to speculate that silencing
NF-kB signaling molecules may enhance cathelicidin transcrip-
tion. Interestingly, inducers of cathelicidin AMP in colonic cells,
the histone deacetylate inhibitor butyrate and trichostatin A,
also inhibit NF-kB (Schauber et al., 2003, 2004). Moreover,
calcineurin inhibitors, shown to suppress p105/p50 nuclear
translocation, enhance the 1,25D3-induced cathelicidin ex-
pression in keratinocytes (Buchau et al., 2008).
Bcl-3 associates exclusively with NF-kB p50 or p52
homodimers. In this study, we found that Bcl-3 silencing
enhanced the 1,25D3-induced cathelicidin expression, thus
showing that Bcl-3 signaling is important to 1,25D3-
mediated cathelicidin regulation in human keratinocytes.
Blocking p50 by a p50 decoy resulted in an increase in the
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1,25D3-mediated cathelicidin expression, thus suggesting
that it is blocking p50 that enhances cathelicidin expression
and may explain a possible mechanism used by Bcl-3.
However, further studies are needed to confirm this
hypothesis.
Interestingly, orally administered vitamin D resulted in the
downregulation of Bcl-3 expression in lesional AD skin in
five out of seven patients tested. In light of the observation
that Bcl-3 can decrease the cathelicidin expression, these
data are consistent with our recent finding that oral
administration of vitamin D3 increases the cathelicidin
expression in lesional skin from AD patients (Hata and Gallo,
2008). Taken together, these data indicate that Bcl-3
signaling plays a crucial role in 1,25D3-associated immune
responses in AD, and that the effects observed with vitamin D
may be due to direct action on the cathelicidin promoter or
indirect action by suppressing the inhibitory action of Bcl-3.
Further clinical trials are needed to confirm the efficacy of
vitamin D as a therapeutic agent, its effects on the Bcl-3
expression, and to determine to what extent it may also be
acting to inhibit Th2 cytokines. Nevertheless, our findings
presented here reveal an important and complex role for Bcl-
3 in regulating innate immune responses in the skin.
Bcl-3 and its deubiquitinase Cyld play important roles in
chemical-induced skin carcinogenesis and cylindromatosis
(Massoumi et al., 2006). To our knowledge it is previously
unreported that, Bcl-3 is upregulated in AD, one of the most
common chronic inflammatory skin diseases. Whether other
inflammatory skin diseases or skin malignancies show altered
levels of Bcl-3 is currently unknown and will be vital
information for defining the role of Bcl-3 in a variety of
cutaneous diseases.
Taken together, the study presented here defines a
previously unknown element regulating immune function of
keratinocytes and establishes Bcl-3 as a potential therapeutic
target in the treatment of AD. On the basis of these
observations, it will be important to investigate whether
disturbed antimicrobial defense in the skin of patients with
other disorders characterized by altered innate immune
responses show changes in Bcl-3, and may therefore benefit
from therapy targeting the Bcl-3 pathway.
MATERIALS AND METHODS
Cell culture and stimuli
Normal human epidermal keratinocytes were grown in serum-free
EpiLife cell culture media (Cascade Biologics, Portland, OR)
containing 0.06mM Ca2þ and 1 EpiLife Defined Growth
Supplement at 37 1C under standard tissue culture conditions. The
cultures were maintained for up to four passages in this media with
the addition of 50Uml1 penicillin and 50 mgml1 streptomycin.
Cells at 60–80% confluence were stimulated with IL-4 (50 ngml1,
R&D Systems, Minneapolis, MN), IL-13 (50 ngml1, R&D Systems),
TNF-a (20 ngml1, R&D Systems), 1,25D3 (1 or 10 nM, Sigma,
St. Louis, MO). NF-kB p50 (NLS) inhibitor and control peptide were
purchased from Imgenex (San Diego, CA) and used at a concentra-
tion of 1 mM. P50 NLS sequence: DRQIKIWFQNRRMKWKK
VQRKRQKLM (p50 NLS sequence is underlined). The inhibitory
mechanism relies on the function as a p50 decoy by blocking the
intracellular recognition mechanisms of p50 NLS. These peptides are
cell permeable through a protein transduction sequence from
antennapedia.
Skin samples
All studies were approved by the Human Research Protection
program at the University of California, San Diego, and were in
adherence to the Declaration of Helsinki Principles. For all
procedures, written informed consent from donors was obtained.
Skin biopsy samples were obtained from lesional and non-lesional
skin of AD patients and from matching sites of healthy donors. For a
subsequent experiment, AD patients received 4000 IUday1 over 21
days, and skin biopsy samples were taken as described earlier (Hata
and Gallo, 2008). All samples were stored at 80 1C until use.
Real-time RT-PCR (qPCR)
Total RNA from skin samples and cultured keratinocytes was
extracted using Trizol (Invitrogen, Carlsbad, CA) and 1 mg RNA
was reverse-transcribed using iScript (Bio-Rad, Hercules, CA). The
expression of cathelicidin was evaluated using a FAM-CAGAGGA
TTGTGACTTCA-MGB probe with primers 50-CTTCACCAGCCCGT
CCTTC-30 and 50-CCAGGACGACACAGCAGTCA-30. For GAPDH
expression, a VIC-CATCCATGACAACTTTGGTA-MGB probe with
primers 50-CTTAGCACCCCTGGCCAAG-30 and 50-TGGTCATGAG
TCCTTCCACG-30 was used as described (Schauber et al., 2006).
qPCR efficiencies for cathelicidin and GAPDH primers and probes
were optimized as published earlier (Schauber et al., 2006).
Predeveloped Taqman assay probes (Applied Biosystems ABI, Foster
City, CA) were used for the analyses of the expressions of Bcl-3,
HBD3, IL-6, and IL-8. All analyses were performed in triplicate from
two to five independent cell stimulation experiments in an ABI Prism
7000 Sequence detection system. Fold induction relative to the
control was calculated using the 2ðDDCtÞ method, where DCt is the
DCt(stimulant/diseased skin)–DCt(vehicle/control skin), DCt is Ct(target)–Ct(GAPDH),
and Ct is the cycle at which the detection threshold is crossed.
Results were considered significant when statistical analysis revealed
Po0.05.
Fluorescence immunohistochemistry
Keratinocytes were grown on chamber slides. After methanol
fixation and subsequent washings in phosphate-buffered saline
(PBS), the slides were blocked in 3% BSA in PBS for 30minutes at
room temperature and stained with a rabbit anti-Bcl-3 antibody or
preimmune serum. After washings in PBS, the slides were reprobed
with a FITC-labelled goat anti-rabbit antibody. After subsequent
washings with PBS, the slides were mounted in ProLong Anti-Fade
reagent containing 40,6-diamidino-2-phenylindole (Molecular
Probes, Eugene, OR) and evaluated with an Olympus BX41
microscope (Olympus, Melville, NY) at original magnification of
 400.
siRNA and transfection
Second or third passage keratinocytes were maintained in serum-free
keratinocyte growth medium (Cascade Biologics) containing
10 ngml1 human recombinant epidermal growth factor (half the
dose compared with Cascade Biologics’s standard composition).
Keratinocytes were transfected with 20 nM siRNA oligonucleotides
using siLentFect (Bio-Rad) for 18–22 hours. siRNA oligonucleotides
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for Bcl-3 (Santa Cruz Biotechnology, Santa Cruz, CA) and a
non-targeted control siRNA (Santa Cruz Biotechnology) were used.
Bcl-3 siRNA is a pool of three target specific 20–25 nt siRNAs
designed to knock down gene expression (sequences: sense strand
(A): AGACACGCCUCUCCAUAUUTT mRNA loc. 422, sense strand
(B): ACAUGCACCUACCCAUACATT mRNA loc. 1519, and sense
strand (C): ACAUCUUCCAUUUCCAUGUTT mRNA loc. 1635). The
efficiency of blockage was evaluated by real-time RT-PCR and
western blot analysis. Blockage efficiency in all experiments was
50–65% for siBcl-3 compared with that for baseline. After transfec-
tion, cells were washed with PBS and then stimulated. These
experiments were repeated using at least two different batches of
primary keratinocytes.
Western blot
Cultured keratinocytes were subsequently lysed in ice-cold RIPA
buffer containing proteinase inhibitors (Roche, Indianapolis, IN).
After centrifugation, equal amounts of protein were mixed with
loading buffer (0.25M Tris-HCl, 10% SDS, 10% glycerol, 5%
b-mercaptoethanol) and loaded onto a 16% Tris-Tricine gel
(GeneMate, Kaysville, UT). After separation, proteins were blotted
onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA)
and blocked in 5% milk (Bio-Rad) in TBS 0.1% Tween 20 for 1 hour
at room temperature. After washings in tris buffered saline (TBS) 0.1%
Tween 20, the membranes were stained with a rabbit anti-Bcl-3
antibody, washed again in TBS 0.1% Tween 20, and reprobed with a
horseradish peroxidase-coupled goat anti-rabbit antibody (DakoCy-
tomation, Glostrup, Denmark). Stained protein was visualized using
the Western Lightning system (PerkinElmer, Boston, MA). Densito-
metric analyses were performed using ImageJ (version 1.37r).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Yuko Oda from the Department of Medicine (Endocrine Unit,
Veterans Affairs Medical Centre, University of California San Francisco) for
advice in siRNA technology. We thank Dr Ju¨rgen Schauber, Dr Mark Peric,
and Sarah Koglin from the Department of Dermatology (Ludwig-Maximilians-
University-Munich, Munich, Germany) for help and technical assistance. This
work was supported by a VA Merit award and NIH grants, AI052453, and
AR45676 to R.L.G. and a grant from The Deutsche Forschungsgemeinschaft
(DFG) to A.S.B (Bu 2212/1-1).
REFERENCES
Bieber T (2008) Atopic Dermatitis. N Engl J Med 358:1483–94
Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K et al. (1993) The
oncoprotein Bcl-3 directly transactivates through kappa B motifs via
association with DNA-binding p50B homodimers. Cell 72:729–39
Brasier AR, Lu M, Hai T, Lu Y, Boldogh I (2001) NF-kappa B-inducible BCL-3
expression is an autoregulatory loop controlling nuclear p50/NF-kappa
B1 residence. J Biol Chem 276:32080–93
Buchau AS, Schauber J, Hultsch T, Stuetz A, Gallo RL (2008) Pimecrolimus
enhances TLR2/6-induced expression of antimicrobial peptides in
keratinocytes. J Invest Dermatol 128:2646–54
Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH (2007) Negative
regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitina-
tion blockade. Science 317:675–8
Chen LF, Greene WC (2004) Shaping the nuclear action of NF-kappaB. Nat
Rev Mol Cell Biol 5:392–401
David M, Ford D, Bertoglio J, Maizel AL, Pierre J (2001) Induction of the IL-13
receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes:
involvement of STAT6, ERK and p38 MAPK pathways. Oncogene
20:6660–8
Elloumi HZ, Holland SM (2008) Complex regulation of human cathelicidin
gene expression: novel splice variants and 50UTR negative regulatory
element. Mol Immunol 45:204–17
Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U
(1992) The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-
kappa B-mediated inhibition. Nature 359:339–42
Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D (1993) The candidate
proto-oncogene bcl-3 encodes a transcriptional coactivator that activates
through NF-kappa B p50 homodimers. Genes Dev 7:1354–63
Hata TR, Gallo RL (2008) Antimicrobial peptides, skin infections, and atopic
dermatitis. Semin Cutan Med Surg 27:144–50
Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell
132:344–62
Howell MD, Boguniewicz M, Pastore S, Girolomoni G, Leung DY (2006a)
Mechanism of HBD-3 deficiency in atopic dermatitis. Clin Immunol
121:332–8
Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE et al.
(2006b) Cytokine milieu of atopic dermatitis skin subverts the innate
immune response to vaccinia virus. Immunity 24:341–8
Howell MD, Novak N, Bieber T, Pastore S, Girolomoni G, Boguniewicz M
et al. (2005) Interleukin-10 downregulates anti-microbial peptide
expression in atopic dermatitis. J Invest Dermatol 125:738–45
Kolls JK, McCray PB Jr, Chan YR (2008) Cytokine-mediated regulation of
antimicrobial proteins. Nat Rev Immunol 8:829–35
Kuwata H, Watanabe Y, Miyoshi H, Yamamoto M, Kaisho T, Takeda K et al.
(2003) IL-10-inducible Bcl-3 negatively regulates LPS-induced TNF-
alpha production in macrophages. Blood 102:4123–9
Liu PT, Stenger S, Tang DH, Modlin RL (2007) Cutting edge: vitamin D-
mediated human antimicrobial activity against Mycobacterium tubercu-
losis is dependent on the induction of cathelicidin. J Immunol
179:2060–3
Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R (2006) Cyld
inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB
signaling. Cell 125:665–77
McKeithan TW, Ohno H, Diaz MO (1990) Identification of a transcriptional
unit adjacent to the breakpoint in the 14;19 translocation of chronic
lymphocytic leukemia. Genes Chromosomes Cancer 1:247–55
Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno H (2003)
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive
anaplastic large cell lymphoma from Hodgkin disease. Blood
101:2789–96
Ong PY, Hamid QA, Travers JB, Strickland I, Al Kerithy M, Boguniewicz M
et al. (2002) Decreased IL-15 may contribute to elevated IgE and acute
inflammation in atopic dermatitis. J Immunol 168:505–10
Rebollo A, Dumoutier L, Renauld JC, Zaballos A, Ayllon V, Martinez AC
(2000) Bcl-3 expression promotes cell survival following interleukin-4
deprivation and is controlled by AP1 and AP1-like transcription factors.
Mol Cell Biol 20:3407–16
Richard M, Louahed J, Demoulin JB, Renauld JC (1999) Interleukin-9
regulates NF-kappaB activity through BCL3 gene induction. Blood
93:4318–27
Rocha S, Martin AM, Meek DW, Perkins ND (2003) p53 represses cyclin D1
transcription through down regulation of Bcl-3 and inducing increased
association of the p52 NF-kappaB subunit with histone deacetylase 1.
Mol Cell Biol 23:4713–27
Schauber J, Dorschner RA, Yamasaki K, Brouha B, Gallo RL (2006) Control of
innate antimicrobial response is cell-type specific and dependent on
relevant microenvironmental stimuli. Immunol 118:509–19
Schauber J, Dorschner RA, Coda AB, Buchau AS, Liu PT, Kiken D et al.
(2007) Injury enhances TLR2 function and antimicrobial peptide
expression through a vitamin D-dependent mechanism. J Clin Invest
117:803–11
2154 Journal of Investigative Dermatology (2009), Volume 129
AS Bu¨chau et al.
BCL-3 Controls Innate Immune Responses
Schauber J, Iffland K, Frisch S, Kudlich T, Schmausser B, Eck M et al. (2004)
Histone-deacetylase inhibitors induce the expression of the cathelicidin
LL-37 in human gastrointestinal cells. Mol Immunol 41:847–54
Schauber J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach W et al.
(2003) Expression of the cathelicidin LL-37 is modulated by short chain
fatty acids in colonocytes: relevance of signalling pathways. Gut
52:735–41
Vita N, Lefort S, Laurent P, Caput D, Ferrara P (1995) Characterization and
comparison of the interleukin 13 receptor with the interleukin 4 receptor
on several cell types. J Biol Chem 270:3512–7
Wang T-T, Nestel F, Bourdeau V, Nagai Y, Wang Q, Liao J et al. (2004)
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of
antimicrobial peptide gene expression. J Immunol 173:2909–12
Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin AS Jr (2001) The
putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1)
transition. Mol Cell Biol 21:8428–36
Xing N, Maldonado ML, Bachman LA, McKean DJ, Kumar R, Griffin MD
(2002) Distinctive dendritic cell modulation by vitamin D(3) and
glucocorticoid pathways. Biochem Biophys Res Commun 297:645–52
Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A et al.
(2007) Increased serine protease activity and cathelicidin promotes skin
inflammation in rosacea. Nat Med 13:975–980
Yu XP, Bellido T, Manolagas SC (1995) Down-regulation of NF-kappa B
protein levels in activated human lymphocytes by 1,25-dihydroxyvita-
min D3. Proc Natl Acad Sci USA 92:10990–4
Zhang MY, Harhaj EW, Bell L, Sun SC, Miller BA (1998) Bcl-3 expression and
nuclear translocation are induced by granulocyte–macrophage colony-
stimulating factor and erythropoietin in proliferating human erythroid
precursors. Blood 92:1225–1234
Zhang Q, Didonato JA, Karin M, McKeithan TW (1994) BCL3 encodes a
nuclear protein which can alter the subcellular location of NF-kappa B
proteins. Mol Cell Biol 14:3915–26
www.jidonline.org 2155
AS Bu¨chau et al.
BCL-3 Controls Innate Immune Responses
